This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vivus Weight-Loss Drug's Failing Math

MOUNTAIN VIEW, Calif. ( TheStreet) -- It's only been six weeks, but the commercial launch of Vivus' (VVUS - Get Report) weight-loss pill Qsymia is already falling well below Wall Street expectations.

Admittedly, it's too early to call the Qsymia launch a total bust and Vivus has cautioned investors to expect a slow rollout. But based on prescription data collected so far, Vivus is highly unlikely to meet the $25 million in Qsymia sales that analysts have forecast for the fourth quarter -- the first significant barometer of the weight-loss drug's launch.

Vivus shares are down 12% to $15.38 in Wednesday trading.

The Qsymia launch math doesn't look pretty:

Doctors have written 5,802 new prescriptions for Qsymia in the five weeks since the drug launched (Sept. 21 through Oct. 19), according to healthcare research firm IMS Health.

Vivus has recommended that doctors write two Qsymia prescriptions for each new patient -- one at the low, titration dose and the second at the middle, recommended dose. Not all doctors are following this advice but roughly speaking, dividing total new Qsymia prescriptions in half gives you an estimate for the actual number of patients.

Through Oct. 19 -- or roughly one-third of the way through the fourth quarter -- there are approximately 2,901 patients on Qsymia, according to IMS data.

That's bad because the fourth-quarter Qsymia consensus sales estimate of $24.5 million (from Bloomberg with 12 analysts contributing forecasts) implies an average of 59,600 patients on the drug.

[Qsymia is priced at approximately $4.50 per day, or $137 per month, or $411 per quarter per patient.]

To be fair to Vivus, these are back-of-the-envelope calculations and data providers like IMS are not capturing all Qsymia prescriptions. But even if you upsize assumptions -- let's say there are 5,000 patients on Qsymia in October and that numbers doubles in November and doubles again in December -- Vivus still won't come close to $25 million in Qsymia sales.

Credit Suisse analyst Lee Kalowski is forecasting $12 million in fourth-quarter Qsymia sales, which I believe is the low estimate on the Street. Based on the current trajectory of new patient starts, Vivus will be hard-pressed to meet Kalowski's conservative forecast.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $1.70 -0.58%
OREX $0.47 1.30%
VVUS $1.56 -0.95%
AAPL $95.31 1.80%
FB $117.54 -0.87%


Chart of I:DJI
DOW 17,767.03 -124.13 -0.69%
S&P 500 2,064.74 -16.69 -0.80%
NASDAQ 4,776.10 -41.4940 -0.86%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs